Medicenna Therapeutics Corp. (MDNA) Reports MDNA209 CD122 Blockade, 3–4x Survival Gain in Mice

Medicenna reported preclinical data showing MDNA209 extended median survival 3-4x in mouse models of acute graft-versus-host disease. The drug blocked IL-2/IL-15 signaling via CD122, expanding the company's Superkine platform into autoimmune disease. Next steps include IND-enabling studies and human trials.

Original reporting
Published Oct 26, 2026, 12:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 1:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medicenna Therapeutics Corp. (MDNA) Reports MDNA209 CD122 Blockade, 3–4x Survival Gain in Mice — source image
Decision brief

The 30-second read

Low
01

Why it matters

The data expands Medicenna's pipeline beyond oncology, suggesting a new autoimmune indication and possible new partnership or financing catalysts.

02

Market read

Early‑stage data may attract speculative interest but limited immediate trading impact.

03

What to watch

Potential competition in the CD122 space and the need for significant funding to advance IND studies.

Relevance 8/10Novelty 8/10Timing: today

Background

Medicenna Therapeutics is a clinical‑stage biotech developing engineered cytokine therapeutics. The MDNA209 candidate targets IL‑2/IL‑15 signaling via CD122.

Market effects

May boost interest in the broader CD122 blockade and Superkine platform space.

Limited to US biotech investors; no broader regional effect.

Low global relevance beyond niche biotech community.

Counterpoint

Preclinical results often fail to translate; investors may remain cautious until human data.

Key entities

  • Medicenna Therapeutics Corp.

    US‑listed biotech (MDNA) reporting preclinical data.

Related articles

$VNRXMed

VolitionRx reports clinical progress across diagnostic platform

VolitionRx (VNRX) reported progress in its Nu.Q diagnostic platform, with high sensitivity and specificity in detecting cancers. Its Nu.Q NETs test is part of a €6.3M French program. The company saw a 134% revenue increase, reduced operating losses, and is in licensing discussions. It also expanded a supply agreement with Fujifilm Vet Systems for a feline cancer test.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.